New Delhi [India], March 9 (ANI): The Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation (EUA) to Serum Institute of India's (SII) COVID-19 vaccine Covovax for adults and for children above the age of 12 years.
New Delhi [India], February 21 (ANI): Hyderabad-based pharmaceutical company Biological E on Monday received emergency use authorisation from Drugs Controller General of India (DCGI) for its COVID-19 vaccine Corbevax for the 12 to 18 age group.
New Delhi [India], February 15 (ANI): The Drugs Controller General of India (DCGI)'s Subject Expert Committee (SEC) has recommended Emergency Use Authorization to Hyderabad-based pharmaceutical company Biological E's COVID-19 vaccine, Corbevax, for the age group 12 to 18 years subject to
New Delhi [India], February 6 (ANI): The Drugs Controller General of India (DCGI) has granted emergency-use permission to the single-dose Sputnik Light COVID-19 vaccine, informed Union Health Minister Mansukh Mandaviya on Sunday.
New Delhi [India], January 30 (ANI): As Hyderabad-based drug maker Bharat Biotech has got regulatory approval to conduct Phase-3 clinical trials of its intranasal COVID-19 vaccine as a booster dose, senior epidemiologist in All India Institute of Medical Sciences (AIIMS) in Delhi, Dr Sanjay
New Delhi [India], January 28 (ANI): The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials of intranasal vaccine BBV154.
New Delhi [India], January 27 (ANI): The Drugs Controller General of India (DCGI) on Thursday granted conditional regular market approval for COVID-19 vaccines Covaxin and Covishield for restricted use in emergency situations in the adult population.
New Delhi [India], January 26 (ANI): The regular market approval from Drugs Controller General of India (DCGI) to COVID-19 vaccine Covishield and Covaxin is expected soon, but only after price fixation which is still underway, official sources told ANI on Wednesday.
New Delhi [India], January 19 (ANI): The Drugs Controller General of India's (DCGI) subject expert committee (SEC) has recommended the regular market approval to Serum Institute of India and Bharat Biotech for their COVID-19 vaccines Covaxin and Covishield with conditions for the adult po
New Delhi [India], January 14 (ANI): The Drugs Controller General of India's (DCGI) Subject Expert Committee (SEC) will continue thorough review of data submitted by the Serum Institute of India (SII) and Bharat Biotech for granting full market approval to Covaxin and Covishield, sources
New Delhi [India], January 14 (ANI): Drugs Controller General of India (DCGI)'s Subject Expert Committee will review applications of Bharat Biotech and Serum Institute of India (SII) for full market approval to Covaxin and Covishield respectively on Friday, sources said.
Gaithersburg/Pune (Maryland/Maharashtra)[US/India], December 29 (ANI): Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII), the world's largest vaccin